Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
Akero Therapeutics (Nasdaq: AKRO) announced upcoming presentations at the 75th Annual AASLD The Liver Meeting® 2024, showcasing data on efruxifermin (EFX) for treating pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH). The presentations include:
1. An oral presentation on EFX's significant improvement of liver fibrosis at Week 96 in the HARMONY study.
2. A late-breaking poster on EFX's reduction of at-risk MASH and near-complete histological disease reversal at Week 96.
3. Another late-breaking poster on AI and digital-based pathology corroborating fibrosis reduction observed with EFX treatment.
All presentations will be given by Dr. Mazen Noureddin from Houston Methodist Hospital. The meeting takes place from November 15-19, 2024, in San Diego.
Akero Therapeutics (Nasdaq: AKRO) ha annunciato le prossime presentazioni alla 75ª Annual AASLD The Liver Meeting® 2024, durante le quali verranno presentati dati su efruxifermin (EFX) per il trattamento della steatoepatite metabolica associata a disfunzione pre-cirrotica (MASH). Le presentazioni includeranno:
1. Una presentazione orale sull'improvement significativo della fibrosi epatica a 96 settimane nello studio HARMONY.
2. Un poster di ultima ora sulla riduzione del MASH a rischio e sulla quasi completa reversibilità istologica della malattia a 96 settimane.
3. Un altro poster di ultima ora sull'uso dell'IA e della patologia digitale a supporto della riduzione della fibrosi osservata con il trattamento EFX.
Tutte le presentazioni saranno tenute dal Dr. Mazen Noureddin dell'Houston Methodist Hospital. L'incontro si svolgerà dal 15 al 19 novembre 2024 a San Diego.
Akero Therapeutics (Nasdaq: AKRO) anunció próximas presentaciones en la 75ª reunión anual de AASLD The Liver Meeting® 2024, mostrando datos sobre efruxifermin (EFX) para el tratamiento de la esteatohepatitis metabólica asociada a disfunción pre-cirróttica (MASH). Las presentaciones incluirán:
1. Una presentación oral sobre la mejora significativa de la fibrosis hepática en la Semana 96 en el estudio HARMONY.
2. Un póster de última hora sobre la reducción de MASH en riesgo y la reversión histológica casi completa de la enfermedad en la Semana 96.
3. Otro póster de última hora sobre la IA y la patología digital corroborando la reducción de la fibrosis observada con el tratamiento EFX.
Todas las presentaciones serán realizadas por el Dr. Mazen Noureddin del Houston Methodist Hospital. La reunión se llevará a cabo del 15 al 19 de noviembre de 2024 en San Diego.
Akero Therapeutics(Nasdaq: AKRO)는 2024년 제75회 연례 AASLD The Liver Meeting®에서 알코올성 간질환(MASH) 전 간경변 대사 기능 이상 치료를 위한 efruxifermin(EFX) 데이터 발표가 예정되었다고 발표했습니다. 발표 내용은 다음과 같습니다:
1. HARMONY 연구에서 96주 차에 EFX의 간 섬유증의 유의미한 개선에 대한 구두 발표.
2. 위험이 있는 MASH 감소와 96주 차에 거의 완전한 병리학적 질병 역전 사례를 다룬 최신 포스터 발표.
3. EFX 치료에서 관찰된 섬유증 감소를 뒷받침하는 AI와 디지털 기반 병리학에 대한 또 다른 최신 포스터 발표.
모든 발표는 휴스턴 메소디스트 병원의 Dr. Mazen Noureddin이 진행합니다. 이번 회의는 2024년 11월 15일부터 19일까지 샌디에고에서 열립니다.
Akero Therapeutics (Nasdaq: AKRO) a annoncé les prochaines présentations lors de la 75e réunion annuelle de l'AASLD The Liver Meeting® 2024, où seront présentées des données sur l'efruxifermin (EFX) pour le traitement de la stéato-hépatite métabolique associée à une dysfonction pré-cirrhotique (MASH). Les présentations incluront :
1. Une présentation orale sur l'amélioration significative de la fibrose hépatique à la semaine 96 dans l'étude HARMONY.
2. Un poster de dernière minute sur la réduction des risques de MASH et l'inversion histologique presque complète de la maladie à la semaine 96.
3. Un autre poster de dernière minute sur l'IA et la pathologie numérique corroborant la réduction de la fibrose observée avec le traitement EFX.
Toutes les présentations seront données par Dr. Mazen Noureddin de l'Houston Methodist Hospital. La réunion se tiendra du 15 au 19 novembre 2024 à San Diego.
Akero Therapeutics (Nasdaq: AKRO) gab die kommenden Präsentationen auf dem 75. jährlichen AASLD The Liver Meeting® 2024 bekannt, in denen Daten zu efruxifermin (EFX) zur Behandlung der prä-zirrhotischen, metabolisch bedingten Steatohepatitis (MASH) präsentiert werden. Die Präsentationen umfassen:
1. Einen mündlichen Vortrag zur signifikanten Verbesserung der Leberfibrose nach 96 Wochen in der HARMONY-Studie.
2. Ein Late-Breaking-Poster zur Reduktion von MASH-Risiken und zur nahezu vollständigen histologischen Umkehrung der Krankheit nach 96 Wochen.
3. Ein weiteres Late-Breaking-Poster über KI und digitalbasierte Pathologie, die die mit der EFX-Behandlung beobachtete Fibrreduzierung belegen.
Alle Präsentationen werden von Dr. Mazen Noureddin vom Houston Methodist Hospital gehalten. Das Treffen findet vom 15. bis 19. November 2024 in San Diego statt.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced an upcoming oral presentation and two late-breaking poster presentations at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 taking place from November 15-19, 2024, in San Diego. The presentations will highlight findings from the 96-week Phase 2b HARMONY study evaluating the efficacy and safety of lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3), along with insights from an analysis using AI and digital-based pathology.
Details for the presentations are as follows:
Title: Efruxifermin Significantly Improved Liver Fibrosis at Week 96 in the HARMONY Study Across Subgroups and Improvements Were Associated With Changes in Biomarkers
Presenter: Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Date/Time: Sunday, November 17, 2024, from 2:00 PM – 2:15 PM PST
Publication Number: 158
Oral Session: MASLD and MASH – New Therapies
Title: Efruxifermin significantly reduced proportion of subjects with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study
Presenter: Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Date/Time: Monday, November 18, 2024, from 8:00 AM – 5:00 PM PST
Publication Number: 5021
Session: Late Breaking Posters
Title: AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study
Presenter: Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Date/Time: Monday, November 18, 2024, from 8:00 AM – 5:00 PM PST
Publication Number: 5047
Session: Late Breaking Posters
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4) in which patients have been treated for up to 96 weeks. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
Deerfield Group
Peg.rusconi@deerfieldgroup.com
FAQ
What is Akero Therapeutics presenting at AASLD The Liver Meeting 2024?
When and where is the 75th Annual AASLD The Liver Meeting 2024 taking place?
Who is presenting Akero Therapeutics' (AKRO) data at the AASLD meeting?
What are the key findings from Akero Therapeutics' (AKRO) HARMONY study?
How is AI being used in Akero Therapeutics' (AKRO) research on efruxifermin?
